Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

South Australian Health and Medical Research Institute, University of Adelaide, Australia;Division of Haematology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia
Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Germany
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
IDIBAPS, University of Barcelona, Spain
Inserm CIC 0802, CHU de Poitiers, France
Division of Hematology and Oncology, University of Leipzig, Germany
Charité - Universitätsmedizin Berlin, Germany
University of Bologna, Italy
VU University Medical Center, Amsterdam, The Netherlands
HEMORIO, Rio de Janeiro, Brazil
Osaka University Graduate School of Medicine, Osaka, Japan
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
The University of Chicago, IL, USA
University of Turin, Orbassano, Italy
Vol. 99 No. 7 (2014): July, 2014